| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |